New Key Statistics Module, Z-Score and F-Score
NAS:SUPN Key Ratios
| Market Cap $ M | 1,626.18 |
| Enterprise Value $ M | 1,396.95 |
| P/E(ttm) | -- |
| PE Ratio without NRI | 111.69 |
| Forward PE Ratio | -- |
| Price/Book | 1.76 |
| Price/Sales | 2.73 |
| Price/Free Cash Flow | 15.66 |
| Price/Owner Earnings | 33.08 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 607.00 |
| EPS (TTM) $ | -0.003 |
| Beneish M-Score | -2.76 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -12.10 |
| y-y EBITDA Growth Rate % | -34.80 |
| EV-to-EBIT | 269.47 |
| EV-to-EBITDA | 15.51 |
| PEG | -- |
| Shares Outstanding M | 54.73 |
| Net Margin (%) | 0.22 |
| Operating Margin % | 2.21 |
| Pre-tax Margin (%) | 0.46 |
| Quick Ratio | 1.43 |
| Current Ratio | 1.70 |
| ROA % (ttm) | 0.09 |
| ROE % (ttm) | 0.14 |
| ROIC % (ttm) | 0.57 |
| Dividend Yield % | -- |
| Altman Z-Score | 3.92 |
| Piotroski F-Score | 5.00 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA y-y | N |
| Cash flow > Earnings | Y |
| Lower Leverage y-y | N |
| Higher Current Ratio y-y | Y |
| Less Shares Outstanding y-y | Y |
| Gross Margin Increase y-y | N |
| Higher Asset Turnover y-y | N |
SUPN Number of Guru Trades
SUPN Volume of Guru Trades
Gurus Latest Trades with NAS:SUPN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:SUPN is held by these investors
Total 4
Supernus Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:SUPN
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers